Clinical Trials Browser

Suspended × Cholangiocarcinoma × lenvatinib × Clear all

NCT03779100 2019-01-28

Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Phase 2 Suspended

Gastrointestinal

Cholangiocarcinoma